Neurovance, Inc. Company Profile

12:47 EDT 31st March 2015 | BioPortfolio

Neurovance has been spun out of Euthymics Bioscience, Inc. to advance EB-1020, a norepinephrine and dopamine-preferring reuptake inhibitor for ADHD. In addition to EB-1020, Neurovance also holds a substantial portfolio of research stage reuptake inhibitors.


News Articles [4 Associated News Articles listed on BioPortfolio]

Neurovance gets $5.5M funding boost

A Series A1 funding round has pulled in an additional $5.5 million for Neurovance.  -More- 

Box: Neurovance Inc. Corporate Profile

Three's company Neurovance Inc. Cambridge, Mass. Technology: Triple reuptake inhibitor for ADHD Disease focus: Neurology Clinical status: Phase II Founded: 2012 by Anthony McKinney, Frank Bymaster, Ga...

Neurovance, Inc.: Series A $7M

Neurovance (Cambridge, MA), a clinical stage pharmaceutical company developing a norepinephrine, dopamine and serotonin triple uptake inhibitor to treat ADHD, closed a $7M Series A financing. Particip...

Neurovance Announces Top-Line Study Results Suggest Lower Abuse Potential for Centanafadine Compared to Stimulants Used for Adult ADHD

—Recent Trials Provide Evidence of Both Efficacy and Reduced Abuse Liability— —Full Results of the Human Abuse Liability Study Presented at the American Coll...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Neurovance Inc.

Neurovance is a neuroscience-focused, clinical-stage biopharmaceutical company that specializes in triple reuptake inhibitors specifically optimized for adult attention deficit hy...

Neurovance, Inc.

Neurovance has been spun out of Euthymics Bioscience, Inc. to advance EB-1020, a norepinephrine and dopamine-preferring reuptake inhibitor for ADHD. In addition to EB-1020, Neurov...

More Information about "Neurovance, Inc." on BioPortfolio

We have published hundreds of Neurovance, Inc. news stories on BioPortfolio along with dozens of Neurovance, Inc. Clinical Trials and PubMed Articles about Neurovance, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Neurovance, Inc. Companies in our database. You can also find out about relevant Neurovance, Inc. Drugs and Medications on this site too.

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Top five promising drugs Phase II (November 2013)
Latest News Clinical Trials Research Drugs Reports Corporate
THE FIVE MOST PROMISING DRUGS ENTERING PHASE II TRIALS Drug Disease Company Sel-G1 Sickle cell anemia Selexys Pharmaceuticals NSI-566 Amyotrophic lateral sclerosis ...

Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record